$AEON
AEON Biopharma, Inc.

2021 Form 10-K Financial Statement

#000110465922038759 Filed on March 28, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4
Revenue $0.00 $2.518M
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $2.518M
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $11.59M
YoY Change
% of Gross Profit 460.17%
Research & Development $7.319M
YoY Change
% of Gross Profit 290.67%
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit 0.0%
Operating Expenses $1.936M $18.91M
YoY Change
Operating Profit -$1.936M -$3.588K
YoY Change -176.82%
Interest Expense $10.79M -$155.0K
YoY Change -6844.89%
% of Operating Profit
Other Income/Expense, Net $10.14M -$5.129M
YoY Change -297.6%
Pretax Income $8.201M -$32.91M
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings $8.201M -$3.588K
YoY Change
Net Earnings / Revenue -0.14%
Basic Earnings Per Share
Diluted Earnings Per Share $237.7K -$1.50
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $497.4K
YoY Change -97.54%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $337.8K
YoY Change 322.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $835.2K $81.00K
YoY Change 944.03%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $276.1M
YoY Change
Other Assets $34.62K
YoY Change -95.67%
Total Long-Term Assets $276.1M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $835.2K $81.00K
Total Long-Term Assets $276.1M $0.00
Total Assets $276.9M $81.00K
YoY Change 346086.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $634.6K
YoY Change -68.27%
Accrued Expenses $200.0K
YoY Change 900.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $834.6K $59.59K
YoY Change 1290.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $17.04M
YoY Change 68.76%
Total Long-Term Liabilities $17.04M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $834.6K $59.59K
Total Long-Term Liabilities $17.04M
Total Liabilities $17.88M $59.59K
YoY Change 29698.98%
SHAREHOLDERS EQUITY
Retained Earnings -$3.588K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $259.1M $21.41K
YoY Change
Total Liabilities & Shareholders Equity $276.9M $81.00K
YoY Change 346086.91%

Cashflow Statement

Concept 2021 2020 Q4
OPERATING ACTIVITIES
Net Income $8.201M -$3.588K
YoY Change
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$1.495M -$5.525M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$276.0M -$1.265M
YoY Change 21632.28%
Cash From Investing Activities -$276.0M -$1.265M
YoY Change 21632.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $270.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 278.0M 24.65M
YoY Change 1031.43%
NET CHANGE
Cash From Operating Activities -1.495M -5.525M
Cash From Investing Activities -276.0M -1.265M
Cash From Financing Activities 278.0M 24.65M
Net Change In Cash 497.4K 17.86M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$1.495M -$5.525M
Capital Expenditures $0.00
Free Cash Flow -$5.525M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
497412
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
834585
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001837607
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40021
CY2021 dei Entity Registrant Name
EntityRegistrantName
Priveterra Acquisition Corp.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3940478
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
300 SE 2nd Street, Suite 600
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33301
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Lauderdale
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2021 dei City Area Code
CityAreaCode
754
CY2021 dei Local Phone Number
LocalPhoneNumber
220-9229
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Entity Shell Company
EntityShellCompany
true
CY2021 dei Auditor Firm
AuditorFirmId
100
CY2021 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2021 dei Auditor Location
AuditorLocation
Princeton, NJ, USA
CY2021Q2 dei Entity Public Float
EntityPublicFloat
332600000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
497412
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
337812
CY2021Q4 us-gaap Assets Current
AssetsCurrent
835224
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
34619
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
81000
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
276079687
CY2021Q4 us-gaap Assets
Assets
276949530
CY2020Q4 us-gaap Assets
Assets
81000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
634585
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
200000
CY2020Q4 pmgmu Promissory Note Related Party
PromissoryNoteRelatedParty
38588
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
834585
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59588
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
7384800
CY2021Q4 pmgmu Deferred Underwriting Discount Noncurrent
DeferredUnderwritingDiscountNoncurrent
9660000
CY2021Q4 us-gaap Liabilities
Liabilities
17879385
CY2020Q4 us-gaap Liabilities
Liabilities
59588
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24310
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16962545
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3588
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-16929855
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
21412
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
276949530
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81000
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1935943
CY2020Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3588
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-1935943
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3588
CY2021 pmgmu Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
10712133
CY2021 pmgmu Transaction Costs Other
TransactionCostsOther
655046
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
79687
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10136774
CY2021 us-gaap Net Income Loss
NetIncomeLoss
8200831
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3588
CY2020Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3588
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
21412
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1199067
CY2021 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
26383165
CY2021 pmgmu Adjustments To Additional Paid In Capital Working Capital Loan Conversion
AdjustmentsToAdditionalPaidInCapitalWorkingCapitalLoanConversion
32000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
8200831
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-16929855
CY2021 us-gaap Profit Loss
ProfitLoss
8200831
CY2020Q4 us-gaap Profit Loss
ProfitLoss
-3588
CY2021 pmgmu Interest Earned On Cash Held In Trust Account
InterestEarnedOnCashHeldInTrustAccount
79687
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10712133
CY2021 pmgmu Transaction Costs Other
TransactionCostsOther
655046
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
372430
CY2021 pmgmu Increase Decrease Franchise Tax Payable
IncreaseDecreaseFranchiseTaxPayable
200000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
613585
CY2020Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3588
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1494788
CY2021 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
276000000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-276000000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270480000
CY2021 pmgmu Net Proceeds From Initial Public Offering
NetProceedsFromInitialPublicOffering
-369212
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7820000
CY2021 pmgmu Proceeds From Working Capital Loan
ProceedsFromWorkingCapitalLoan
100000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
35192
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
73780
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
277992200
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
497412
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
497412
CY2021 pmgmu Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2021Q4 pmgmu Transaction Costs
TransactionCosts
15630212
CY2021Q4 pmgmu Sale Of Stock Underwriting Fees
SaleOfStockUnderwritingFees
5520000
CY2021Q4 pmgmu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
9660000
CY2021Q4 pmgmu Sale Of Stock Other Offering Costs
SaleOfStockOtherOfferingCosts
450212
CY2021Q4 pmgmu Transaction Costs Included In Operation Statement
TransactionCostsIncludedInOperationStatement
655046
CY2021 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2021 pmgmu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2021 pmgmu Deferred Underwriters Discount Payable Charged To Additional Paid In Capital
DeferredUnderwritersDiscountPayableChargedToAdditionalPaidInCapital
9660000
CY2021 pmgmu Conversion Of Working Capital Loans To Private Placement Warrants
ConversionOfWorkingCapitalLoansToPrivatePlacementWarrants
100000
CY2021 pmgmu Change In Value Of Common Stock Subject To Possible Redemptions
ChangeInValueOfCommonStockSubjectToPossibleRedemptions
26383165
CY2020Q4 pmgmu Deferred Offering Costs Paid By Sponsor In Exchange For Issuance Of Common Stock
DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfCommonStock
25000
CY2020Q4 pmgmu Deferred Offering Costs Paid By Promissory Note
DeferredOfferingCostsPaidByPromissoryNote
35000
CY2020Q4 pmgmu Accrued Deferred Offering Costs
AccruedDeferredOfferingCosts
81000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. ORGANIZATION AND BUSINESS OPERATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Organization and General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Priveterra Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on November 17, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had not commenced any operations. All activity for the period from November 17, 2020, the Company’s inception, through December 31, 2021, relates to the Company’s formation and the initial public offering (“IPO”), described below, and identifying a target company for a business combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO and unrealized gains and losses on the change in fair value of it warrants. The Company has selected December 31 as its fiscal year end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s sponsor is Priveterra Sponsor, LLC, a Delaware limited liability company (the “Sponsor”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s IPO was declared effective on February 8, 2021 (the “Effective Date”). On February 11, 2021, the Company consummated an IPO of 27,600,000 units at $10.00 per unit (the “Units”), which includes the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000 Units, at $10.00 per Unit, generating gross proceeds of $276,000,000, which is discussed in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the IPO, the Company consummated the sale of 5,213,333 warrants (the “Private Placement Warrants”), at a price of $1.50 per warrant, which is discussed in Note 4. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, generating gross proceeds of $7,820,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Transaction costs of the IPO amounted to $15,630,212 consisting of $5,520,000 of underwriting fees, $9,660,000 of deferred underwriting fees, and $450,212 of other offering costs. Of the transaction costs, $655,046 is included in offering costs on the statements of operations and $14,975,165 is included in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trust Account</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the IPO on February 11, 2021, $276,000,000 ($10.00 per Unit) from the net offering proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”), located in the United States with Continental Stock Transfer &amp; Trust Company acting as trustee and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its franchise and income tax obligations, if any, the proceeds from the Company’s IPO and the sale of the Private Placement Warrants will not be released from the Trust Account until the earliest of (i) the completion of initial Business Combination, (ii) the redemption of the Company’s public shares if the Company does not complete an initial Business Combination within 24 months from the closing of the IPO, subject to applicable law, or (iii) the redemption of the Company’s public shares properly submitted in connection with a stockholder vote to amend its amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company has not consummated an initial business combination within 24 months from the closing of the IPO or with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a stockholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The shares of common stock subject to redemption are recorded at a redemption value and classified as temporary equity upon the IPO, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their founder shares and public shares in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to their founder shares and public shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete the initial Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company will have 24 months from the closing of the IPO to complete the initial Business Combination (the “Combination Period”). However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.10 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Company’s IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s liquidity needs up to February 11, 2021, the date of the IPO, had been satisfied through a capital contribution from the Sponsor of $25,000 (see Note 5) for the founder shares and the loans under an unsecured promissory note from the Sponsor of $73,295 (see Note 5). In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company's IPO was on February 11, 2021. As of December 31, 2021, the Company had $497,412 in its operating bank account, and working capital of $200,639 (excluding taxes payable which is funded by earnings from the Trust Account).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has approximately <span style="-sec-ix-hidden:Hidden_8JPyuj12u0i7cNP_ITI1Wg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$497,000</span></span> in cash and approximately <span style="-sec-ix-hidden:Hidden_KrG6AX5pd0KpS1piMEaWdw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$835,000 </span></span>in current liabilities as of December 31, 2021, and has incurred and expects to incur additional significant costs in pursuit of its financing and acquisition plans. Additionally, the Company has until February 11, 2023 to consummate a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with FASB ASC Topic 205-40, “Presentation of Financial Statements– Going Concern,” Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. The Company intends to complete a Business Combination before the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2021Q4 pmgmu Transaction Costs Included In Equity Statement
TransactionCostsIncludedInEquityStatement
14975165
CY2021 pmgmu Investments Maximum Maturity Term
InvestmentsMaximumMaturityTerm
P185D
CY2021 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2021 pmgmu Condition For Future Business Combination Use Of Proceeds Percentage
ConditionForFutureBusinessCombinationUseOfProceedsPercentage
10.00
CY2021 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2021 pmgmu Redemption Limit Percentage Without Prior Consent
RedemptionLimitPercentageWithoutPriorConsent
100000
CY2021Q4 pmgmu Cash At Operating Bank Account
CashAtOperatingBankAccount
497412
CY2021Q4 pmgmu Working Capital
WorkingCapital
200639
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liability. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
497412
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021 pmgmu Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2021 pmgmu Investments Maximum Maturity Term
InvestmentsMaximumMaturityTerm
P185D
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2021 pmgmu Amount Of Federal Depository Insurance Coverage
AmountOfFederalDepositoryInsuranceCoverage
250000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
276000000
CY2021 pmgmu Temporary Equity Proceeds Allocated To Warrants
TemporaryEquityProceedsAllocatedToWarrants
-11408000
CY2021 pmgmu Common Stock Issuance Costs
CommonStockIssuanceCosts
-14975165
CY2021 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
26383165
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
276000000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 pmgmu Deferred Fee Per Unit
DeferredFeePerUnit
0.35
CY2021Q4 pmgmu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
9660000
CY2021Q4 pmgmu Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3
CY2021 pmgmu Advance Notice Prior To Applicable Deadline Affiliates Or Designees Must Deposit Into Trust Account
AdvanceNoticePriorToApplicableDeadlineAffiliatesOrDesigneesMustDepositIntoTrustAccount
P30D
CY2021 pmgmu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2021 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombination
P18M
CY2021 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2021 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombination
P18M
CY2021 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2021Q4 pmgmu Maximum Borrowing Capacity Of Related Party Promissory Note
MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
266964
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 pmgmu Initial Business Combination Shares Issuable As Percent Of Outstanding Share
InitialBusinessCombinationSharesIssuableAsPercentOfOutstandingShare
0.01
CY2020Q4 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0
CY2020Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 pmgmu Effective Income Tax Rate Reconciliation Nondeductible Expense Offering Costs Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfferingCostsAmount
0.017
CY2020Q4 pmgmu Effective Income Tax Rate Reconciliation Nondeductible Expense Offering Costs Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfferingCostsAmount
0.000
CY2021 pmgmu Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent
-0.274
CY2020Q4 pmgmu Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.047
CY2020Q4 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.210
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
7384800
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25360
CY2021Q4 pmgmu Deferred Tax Assets Capitalized Start Up And Organization Costs
DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts
364454
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
389814
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
389814
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-389814
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
389814
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
389814
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210

Files In Submission

Name View Source Status
0001104659-22-038759-index-headers.html Edgar Link pending
0001104659-22-038759-index.html Edgar Link pending
0001104659-22-038759.txt Edgar Link pending
0001104659-22-038759-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmgmu-20211231.xsd Edgar Link pending
pmgmu-20211231x10k.htm Edgar Link pending
pmgmu-20211231x10k_htm.xml Edgar Link completed
pmgmu-20211231xex31d1.htm Edgar Link pending
pmgmu-20211231xex31d2.htm Edgar Link pending
pmgmu-20211231xex32d1.htm Edgar Link pending
pmgmu-20211231xex32d2.htm Edgar Link pending
pmgmu-20211231_cal.xml Edgar Link unprocessable
pmgmu-20211231_def.xml Edgar Link unprocessable
pmgmu-20211231_lab.xml Edgar Link unprocessable
pmgmu-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending